With new variants, will COVID-19 tests still work?

Staff in blue PPE at the IVAC vaccine facility in Vietnam work with few dozen chicken eggs, which are helping to manufacture a new type of COVID-19 vaccine.

As the pandemic enters its second year, there are real reasons to celebrate—safe and effective vaccines have been developed and rolled out in record time; new, more affordable and transportable vaccine formulations are close behind; and multilateral initiatives like COVAX and the ACT Accelerator have increased global access to lifesaving tools.

Though these achievements deserve celebration, our work as a global community has only just begun.

This month, Nikolaj Gilbert advocates for equitable access to medical oxygen; my colleagues and I unveil new variant-specific diagnostic dashboards for health officials; Cathy Ndiaye explains how countries are preparing for mass vaccination; Miren Iturriza-Gomara shares lessons from rotavirus for SARS-CoV-2; and Rachana Parikh and Bhushan Girase highlight the pandemic’s impact on mental health in India.

Neha Agarwal
Associate Director, Diagnostics

A worker at the IVAC vaccine facility in Vietnam, one of the sites working on a new COVID-19 vaccine, NDV-HXP-S. Photo: PATH/Matthew Dakin.

A year into COVID-19, medical oxygen scarcity still costing lives

Oxygen access is a matter of life or death. PATH CEO Nikolaj Gilbert calls on the public health community to do more to increase equitable access to medical oxygen.

Man gets a COVID-19 nasal swab by a health care worker in a mask, gloves, and face shield.

With new variants, will COVID-19 tests still work?

PATH Diagnostics launches new variant-specific dashboards to help health officials make sense of which COVID-19 tests are still available—and which ones still work.

A health worker in Senegal pulls a vaccine vial out of a cold storage vaccine carrier.

How governments are preparing for mass vaccination

Ending the pandemic hinges on all countries being able to vaccinate their people. PATH Senegal’s Cathy Ndiaye, PhD, explains what it takes to deliver COVID-19 vaccines at scale.

Virus variants and vaccine efficacy

Virus variant research has been making recent headlines, but it’s nothing new. PATH scientist Miren Iturriza-Gomara, PhD, shares four lessons from rotavirus for SARS-CoV-2.

“It’s a home run for protection. I think it’s a world-class vaccine.”

—Dr. Bruce Innis of PATH's Center for Vaccine Innovation and Access, which has coordinated the development of NDV-HXP-S, a new type of COVID-19 vaccine recently featured in The New York Times.

PATH in the news

Researchers are hatching a low-cost coronavirus vaccine
The New York Times

A new formulation entering clinical trials in Brazil, Mexico, Thailand, and Vietnam could change how the world fights the pandemic. PATH’s Bruce Innis, MD, discusses this promising new vaccine—and PATH’s role in developing it—with renowned science journalist Carl Zimmer.

Keeping COVID vaccines cold isn't easy. These ideas could help.
MIT Technology Review

New formulas and off-grid approaches could help mRNA vaccines get to more places around the world. PATH’s vaccine vial monitors are highlighted, and Pat Lennon explains the importance of thermostable vaccines in extending reach and access.

GFF launches $1.2B campaign for women's, children's health services
Devex

Since the start of COVID-19, the Global Financing Facility for Women, Children, and Adolescents (GFF) has been sounding the alarm about the pandemic’s toll on women and children. PATH’s Pauline Irungu speaks to the impact in Kenya and the importance of ensuring gender equality.

Protect global progress

DONATE >

PATH is committed to respecting your privacy. Please read our privacy notice to understand how we use your personal information, and how we keep it safe.

PATH
Mail: PO Box 900922 | Seattle, WA 98109
Street: 2201 Westlake Avenue, Suite 200
Seattle, WA 98121
Tel: 206.285.3500 | Fax: 206.285.6619
Web: path.org